The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Researchers have developed a drug shown to significantly extend survival time for patients with glioblastoma, the most common primary brain tumor in adults, according to results of a new trial.